Home › Compound Library › 5-Amino-1MQ

5-Amino-1MQ

Peptideoral · inferred

Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor. Not a peptide but often classified with peptide therapies. Blocks NNMT, increasing intracellular NAD+ and SAM (S-adenosylmethionine), promoting fat loss and metabolic health. Oral half-life ~7 hours in rats. Reversed high-fat diet-induced obesity in mice. No human clinical trials published.

Projected serum levels — 50 mg, once daily

5-Amino-1MQ
5-Amino-1MQ modeled serum levels, 50 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 50 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 8.7 mg, trough ≈ 0.032 mg body load. Population-based estimate over 15 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Oral
Model confidence
inferred
Half-life
2.5 h
Common dose
50 mg
Suggested maximum
150 mg/day
Reference dose range
25–150 mg (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Dolutegravir (DTG / Tivicay) + 5-Amino-1MQ Transporter inhibition

    Dolutegravir (DTG / Tivicay) inhibitor of OCT2 may alter 5-Amino-1MQ absorption / distribution

  • moderate
    Trimethoprim/Sulfamethoxazole (Bactrim) + 5-Amino-1MQ Transporter inhibition

    Trimethoprim/Sulfamethoxazole (Bactrim) inhibitor of OCT2 may alter 5-Amino-1MQ absorption / distribution

Serum checks 2 modeled interaction pairings for 5-amino-1mq across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Neelakantan H et al. · Biochemical Pharmacology, 2018 DOI

    Landmark study showing 5-amino-1MQ treatment reversed diet-induced obesity in mice by 30% with no change in food intake, while reducing fat mass, shrinking adipocyte size, and increasing NAD+ content.

  2. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase Neelakantan H et al. · Journal of Medicinal Chemistry, 2017 DOI

    SAR study establishing 5-amino-1MQ as the lead NNMT inhibitor with favorable potency, selectivity, and membrane permeability from a series of substituted quinolinium compounds.

  3. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization Hong S et al. · Nature Medicine, 2015 DOI

    Established NNMT as a key metabolic regulator linking NAD+ salvage and methionine metabolism, providing the mechanistic rationale for NNMT inhibition as an anti-obesity strategy.

3 published studies referenced in the app, each with a plain-language summary.